HomeProductsBioactive CompoundsGPCR & G Protein TargetsAdenosine ReceptorFostamatinib
Chemical structure of CAS 901119-35-5

Fostamatinib

CAS No.901119-35-5
MDL No.MFCD16628163
MFC23H26FN6O9P
MW580.50
InChI KeyGKDRMWXFWHEQQT-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.901119-35-5
Product NameFostamatinib

Biological Targets

SYK

Associated Conditions

lymphoma·systemic lupus erythematosus·COVID-19·IGA glomerulonephritis·rheumatoid arthritis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Fostamatinib for persistent/chronic adult immune thrombocytopenia.

Immunotherapy • Vol. 10, Issue 1 • 2018
PMID: 28967793DOI: 10.2217/imt-2017-0097

Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Rheumatology international • Vol. 36, Issue 8 • 2016
PMID: 27113955DOI: 10.1007/s00296-016-3482-7

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

Pharmacology research & perspectives • Vol. 3, Issue 5 • 2015
PMID: 26516587PMC: PMC4618646DOI: 10.1002/prp2.175

Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).

Journal of clinical pharmacology • Vol. 55, Issue 3 • 2015
PMID: 25280085DOI: 10.1002/jcph.406

Documentation

Similar Products